RespireRx Pharmaceuticals Inc RSPI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RSPI is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.02
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $377,393.01
- Volume/Avg
- 576,203 / 10.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
RespireRx Pharmaceuticals Inc is engaged in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. The pipeline products of the company are dronabinol which is developed for the treatment of OSA (Obstructive Sleep Apnea), a form of sleep apnea; CX1739 for the treatment of chronic central sleep apnea; CX717 and CX1942 is an injectable dosage for respiratory depression or vaso-occlusive passes associated with sickle cell disease. The company also focuses on developing another class of compounds called ampakines for the treatment of various respiratory disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 2
- Website
- http://www.respirerx.com
Valuation
|
Metric
|
RSPI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
RSPI
Financial Strength
|
Metric
|
RSPI
|
|---|---|
Quick Ratio | 0.00 |
Current Ratio | 0.01 |
Interest Coverage | −3.12 |
Quick Ratio
RSPI
Profitability
|
Metric
|
RSPI
|
|---|---|
Return on Assets (Normalized) | −2,286.13% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
RSPI
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Psvthrcsy | Hvl | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Zkttqky | Qvjgkh | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Dnhqgxvhw | Rhryhb | $98.8 Bil | |
MRNA
| Moderna Inc | Wkwjkvb | Gfvvk | $38.8 Bil | |
ARGX
| argenx SE ADR | Clyfbnnj | Wzxm | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Lybtmwrg | Jryp | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mdxcljrl | Ncwczl | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vdsgnqrh | Pvjkg | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Djwrgjwt | Hwdljgx | $12.4 Bil | |
INCY
| Incyte Corp | Cjtqxzgmr | Qhgqkw | $11.9 Bil |